Loading
Qlinea Stock: price and insider trades · Sweden
Qlinea: what insiders have been doing
Insider filings for Qlinea are scarce in the Finansinspektionen feed, the latest one published on 10 November 2025. This page will fill in as new trades are disclosed. Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 24,099 of 24,148 companies
3.2
score / 100
Value4
Quality3
FCF yld-54%
Earn yld-59%
EV/EBITDA·
ROE-76%
Gross mgn-15%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
SEK 16.45
Analyst consensus
Income statement
RevenueSEK 11.1M
Gross profit-SEK 1.7M-15% margin
EBITDA-SEK 161M-1451% margin
Net income-SEK 182.5M-1644.3% margin
Valuation
P/Book1.1x
Beta0.57
Balance sheet & cash
Market capSEK 311.7M
Total debtSEK 5.8M
Free Cash Flow-SEK 169.7M
Debt / Equity4%
Profitability & ownership
ROE-75.5%
ROA-37.0%
% insiders14.0%
% institutions26.3%
Last declaration on 10 November 2025
Declarations1 total
4,000 shares@ SEK 25.000.032% mcap100.0% of flowBTA (betald tecknad aktie)ISIN SE0026577520FI:A003T485-1
1 of 1 declaration
About Qlinea
Qlinea is a company focused on the health and pharmaceutical sector, dedicated to developing innovative solutions for medical diagnostics. It is listed on the XSTO exchange.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
